Recreational methamphetamine (METH) use is common in many areas of the United States, and its prevalence continues to increase [1] . METH use and human immunodeficiency virus (HIV) infection frequently coexist, perhaps, in part, because of the association of METH use with behaviors that carry a high risk for infection [2] [3] [4] [5] . Interactions between METH use and HIV infection are of public health concern for 3 principal reasons. First, experimental evidence from cell cultures and animal models suggests that METH exposure can accelerate feline immunodeficiency virus (FIV) replication [6] , potentially hastening progression to AIDS and death. Second, the specific pathogenic mechanisms by which METH influences replication may be amplified in the central nervous system (CNS) [6] , raising the possibility of additive or synergistic neurological damage and disability in HIV-infected METH users. Third, factors such as reduced access to medical care and inadequate adherence to the therapy regimen may limit the ability of METH users to benefit from highly active antiretroviral therapy (HAART). In the present study, we evaluated potential interactions between METH use and HIV infection by measuring HIV loads in current METH users and abstinent former abusers and comparing them to subjects with no history of METH dependence or abuse. To address the possibility that the effects of METH use on virus load are amplified in the CNS, we measured virus load in cerebrospinal fluid (CSF) as well as in blood plasma. To assess the potential influence of METH use on HAART
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SUBJECTS AND METHODS

Subjects.
Participants in the present study comprised 230 volunteers who were enrolled in various longitudinal studies at the HIV Neurobehavioral Research Center, University of California, San Diego, between 1996 and 2002. A subset of this group ( ) participated in a study conducted to detern p 142 mine whether and by what mechanisms abuse of METH enhances CNS injury in the context of HIV infection. Data from subjects in this subset were obtained at baseline visits. All other subjects were participating in other studies, which required multiple visits. Data from these subjects were obtained at the first visit at which study criteria were met. All subjects had HIV infection documented by serologic testing. Informed consent was obtained according to a protocol approved by the institutional human-subjects review panel.
For purposes of analysis, subjects were classified into 3 groups: . The METH + Tox Ϫ group ( ) comprised subjects who were forn p 66 mer METH users and who met criteria for METH dependence at some time in the past but who, at the time of evaluation, reported being free of METH dependence for at least 30 days and had negative urine toxicology results for METH at the time of lumbar puncture and blood sampling. Former METH users were defined as individuals who received a diagnosis of lifetime METH dependence at some point in the individual's life, on the basis of the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria [7] , as ascertained by the Structured Clinical Interview for Substance Abuse and Dependence. In addition, members of this group had received a diagnosis of METH dependence or abuse during the preceding year, on the basis of DSM-IV criteria. The METH Ϫ Tox Ϫ group ( ) comprised subjects who were n p 76 never METH dependent and had negative urine toxicology results at the time of evaluation. The Tox + group ( ) comn p 88 prised subjects who had positive urine toxicology results at the time of study evaluation.
Clinical evaluations. Each subject underwent a comprehensive neuromedical evaluation that was performed by use of structured clinical data forms that assessed medical history, history of medication use, antiretroviral medications, self-reported adherence to the therapy regimen, neurological and general physical examinations, and laboratory studies, including CD4 + lymphocyte (CD4) counts, routine hematology, and chemistry measurements. Participants were assessed to ensure that there was no clinical evidence of CNS opportunistic disease. From a subset of 175 subjects, 5-15 mL of CSF was obtained by lumbar puncture, and samples were aliquoted and stored at Ϫ70ЊC. [9] . HAART was defined as an antiretroviral drug regimen containing у3 antiretroviral medications.
Laboratory measures.
We measured HIV RNA loads in plasma and CSF by reverse-transcriptase polymerase chain reaction (RT-PCR), using the Amplicor HIV-1 Monitor Test (Roche Molecular Systems). For CSF, an ultrasensitive version of the assay, with a nominal detection limit of 50 copies/mL, was used; whereas, for plasma, the standard assay, with a nominal detection limit of 400 copies/mL, was used. CD4 counts were quantified by a fluorescence-activated cell sorter. CSF white blood cells were measured by manual microscopy. Urine toxicology was assessed by use of the Rapid Drug Screen system (Phamatech) . Urine toxicology results were determined for amphetamines, cocaine, barbiturates, tetrahydrocannabinol (THC), opiates, benzodiazepines, and phencyclidines. In this assay, the detection limit for METH is 500 ng/mL [10, 11] .
Statistical analyses.
To compare continuous variables among the 3 groups, 1-way analysis of variance (ANOVA) was used. When the overall group effect was significant ( ), P ! .05 pair-wise group comparisons were performed by post hoc Tukey honest significant difference test. For categorical variables, x 2 test was performed; significant results were explored further by post hoc, pair-wise comparisons. HIV RNA values were log 10 transformed before analysis. The assay nominal detection limits for each fluid were used as lower limit cutoffs for HIV RNA values (plasma, 2.60 copies/mL; and CSF, 1.70 log copies/mL). Although some deviation from normality on the log-transformed virus loads still existed, the large sample properties of the sampling distribution of the ANOVA and analysis of covariance (ANCOVA) estimators permitted parametric analysis methods. F values are reported. When the assumptions of an ANOVA are met, the F test (variance ratio test), which is the ratio of the between-groups variability to the error variability (taking into account their respective degrees of freedom), follows an F distribution. To assess the effects of HAART status, the cohort was divided by HAART status into 2 subgroups: 1 group included all subjects receiving HAART and the other included all subjects not receiving HAART. Plasma HIV RNA loads were compared by METH-use status separately within each HAART-status subgroup. The subgroup of subjects not receiving HAART (n p ) comprised 82 subjects not receiving ART and 15 receiving 97 mono-or dual-drug therapy. The subjects receiving mono-or dual-drug therapy were distributed among the groups as follows: HAART) , and CSF HIV RNA loads were compared among the METH-use-status groups within both HAART-status subgroups. Within the subset of 175 subjects for whom data on CSF were available, the subgroup of subjects not receiving HAART ( ) comprised 63 subjects not receiving ART and n p 73 10 receiving mono-or dual-drug therapy, and the remaining subjects were receiving HAART ( ). CSF HIV RNA loads n p 102 were compared by METH-use-status group within the subgroup of subjects not receiving HAART. There was no significant effect of METH-use-status group on CSF HIV RNA loads ( ; F p .54 ). The group of 102 subjects receiving HAART was com-P p .59 
DISCUSSION
METH stimulates secretion of tumor necrosis factor (TNF)-a in splenocytes from retrovirus-infected mice [12] . Similarly, cocaine, a recreational stimulant with prominent dopaminergic effects that are similar to those of METH, increases production of TNF-a and HIV replication in human peripheral blood mononuclear cells [13] and stimulates viral replication in human peripheral blood leukocytes implanted into severe combined immunodeficient mice [14] . These findings suggest that stimulants such as METH might increase virus loads in humans by dysregulating inflammatory cytokine production. The present study has found that, in fact, plasma virus loads were higher in Tox + subjects than in METH + Tox Ϫ subjects or METH Ϫ Tox Ϫ subjects. Although this intriguing finding is consistent with the in vitro data, further analyses demonstrated a compelling alternative explanation for the increased virus loads seen in Tox + subjects. More than half of the subjects in this study were receiving HAART. HAART is prescribed to suppress viral replication, and its effects on virus load typically are very significant. Thus, declines of 100-1000-fold from baseline are quite common. We therefore considered it important to assess whether HAART effects modified the influence of METH use on virus load. Indeed, subgroup analyses demonstrated that, compared with subjects in the other groups, Tox + subjects had increased plasma virus loads only if they were receiving HAART. Untreated Tox + subjects and those receiving suboptimal therapy had virus loads statistically indistinguishable from those of subjects in the other groups. This is not consistent with a direct biological effect of METH use itself on viral replication. Rather, it suggests that recent METH use and ART interact in their effects on virus load. Antiretroviral medications suppress viral replication only if drug concentrations are maintained at levels greater than a certain, drug-specific threshold. Inadequate adherence to strict medication administration schedules can allow concentrations to fall below these thresholds, resulting in a rebound of viral replication [15, 16] . Enhanced elimination of antiretrovirals via metabolic pathways due to drug-drug interactions also may lower concentrations below these thresholds. Thus, the increase in virus load that we found among Tox + subjects receiving HAART may be due to poor adherence or to altered metabolism of antiretroviral medications. Although no consistent reports of altered drug metabolism related to METH use exist, there is substantial literature on impaired adherence to the therapy regimen among stimulant users [17, 18] . Impaired adherence to the therapy regimen, in turn, is believed to contribute to less-effective inhibition of viral replication and to the development of resistance to antiretroviral drugs. We collected selfreports of adherence to the HAART regimen and found these to be similar in Tox + subjects, compared with subjects in the other groups. However, self-reports of adherence to the therapy regimen are frequently inaccurate.
It is possible that some METH + Tox Ϫ subjects falsely reported abstinence from METH during the 30 days before evaluation. If so, virus loads in these subjects would be expected to be similar to those of Tox + subjects. Including these subjects would therefore introduce a conservative bias, favoring the null hypothesis of no group differences. In fact, we observed a robust and statistically significant difference.
Recreational drug users typically do not limit themselves to 1 substance, but instead use drugs that are available and affordable. This raises the possibility that use of substances other than METH might explain the increased virus loads seen in our subjects. To address this possibility, we replicated our initial analysis after excluding subjects who tested positive for any drugs of abuse other than METH (excluding marijuana). Comparable results were obtained. Although this approach does not eliminate the possibility that these subjects had used other substances recently, it does diminish the possibility that other drugs could account for the observed effects on virus load.
For several reasons, the CNS is a particularly important site for interactions between METH and HIV. METH penetrates the brain and CSF rapidly because of its lipid solubility and is sequestered in the CNS [26, 27] . Virus-infected cells in the CNS may be selectively affected by METH. Thus, Gavrilin et al. [6] showed that METH exposure dramatically enhances FIV replication in infected brain astrocytes expressing the chemokine receptor CXCR4. Both FIV and HIV are able to use this receptor, which is expressed on astrocytes and immune system cells [6] . Additionally, METH may injure the brain microvascular endothelium, potentiating CNS tissue infiltration by HIVinfected monocytes [28] . These observations suggest that the effects of METH on immune dysregulation and stimulation of virus replication are likely to be enhanced in the brain. Indeed, previous research has found that HIV encephalitis is more prevalent among drug users, compared with nonusers [29] . Despite these observations, we found no evidence of increased CSF virus load in METH users. We plan to address the effects of METH use on cytokine and chemokine concentrations in CSF in separate studies.
We have found that HAART, as expected, effectively lowers virus loads in METH + Tox Ϫ subjects, but not in Tox + subjects. Understanding HAART efficacy in METH users is important for a number of reasons. First, HIV-infected substance abusers frequently have diminished access to health care [19] [20] [21] , and health care providers may be less motivated to treat them [22] [23] [24] . Comorbid conditions associated with drug use, such as higher rates of mood disorders and hepatitis than among nonusing peers, can present obstacles to effective treatment [5, 25] . Despite concerns that the complexities of HAART therapy make it impractical for persons with a history of drug abuse, our findings demonstrate that former METH users who maintain abstinence can effectively suppress HIV replication with potent ART. These data suggest that providers involved in the clinical care of HIV-infected persons who are METH users will need to make efforts to get their patients into substance abuse treatment programs to assist them in achieving stable abstinence. Once abstinence is achieved, the responses to ART by former METH-dependent persons are similar to those of non-substance abusing control subjects.
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